ACALABRUT

Acalabrutinib Capsules 100 mg (Calquence) are a next-generation targeted anti-cancer therapy used for the treatment of certain B-cell malignancies, including Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. This medication belongs to the class of selective Bruton’s Tyrosine Kinase (BTK) inhibitors and works by specifically blocking the BTK enzyme, which plays a crucial role in the growth and survival of cancerous B-cells. By inhibiting this pathway, Acalabrutinib helps slow down the progression of the disease and promotes the natural death of malignant cells while minimizing damage to healthy cells.

Administered orally, typically as a 100 mg capsule taken twice daily, it offers a convenient and effective treatment option, particularly for patients who are intolerant to or have relapsed after other therapies. Compared to earlier BTK inhibitors, Acalabrutinib is designed to be more selective, which may result in a more favorable side effect profile, although patients may still experience headache, diarrhea, fatigue, or increased risk of infections and bleeding. Regular monitoring and medical supervision are essential during treatment to ensure safety and effectiveness. With its targeted action and improved tolerability, Acalabrutinib has become an important advancement in the management of chronic and difficult-to-treat blood cancers.